Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

Offering mailed self-testing for HIV encouraged patients to test themselves for HIV but require methods of improving ...

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

An annual jab to protect against HIV “shows potential”, according to an early study. Millions of people around the world are ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

The advent of effective antiretroviral therapy (ART) has increased the lifespan of many people living with HIV. As a result, ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...